{"id":1986,"date":"2010-02-01T12:06:00","date_gmt":"2010-02-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/optimaler-hba1c-zielwert-bei-diabetes-mellitus-typ-2-weiter-umstritten"},"modified":"2010-02-01T12:06:00","modified_gmt":"2010-02-01T11:06:00","slug":"optimaler-hba1c-zielwert-bei-diabetes-mellitus-typ-2-weiter-umstritten","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/optimaler-hba1c-zielwert-bei-diabetes-mellitus-typ-2-weiter-umstritten","title":{"rendered":"Optimaler HbA1c-Zielwert bei Diabetes mellitus Typ 2 weiter umstritten"},"content":{"rendered":"<p>Anfang Oktober fand in Wien die Jahrestagung der European Association for the Study of Diabetes (EASD) statt. Ein im Verlauf des Kongresses heftig diskutiertes Thema war wieder die Definition des optimalen HbA1c-Werts in der Therapie des Typ-2-Diabetes. Derzeit nennen die American Diabetes Association (ADA) und die EASD in ihren Leitlinien einen Zielwert von HbA1c < [&hellip;]\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anfang Oktober fand in Wien die Jahrestagung der European Association for the Study of Diabetes (EASD) statt. Ein im Verlauf des Kongresses heftig diskutiertes Thema war wieder die Definition des optimalen HbA1c-Werts in der Therapie des Typ-2-Diabetes. Derzeit nennen die American Diabetes Association (ADA) und die EASD in ihren Leitlinien einen Zielwert von HbA1c < [&hellip;]\n<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2912,3860,155,2395,1085,3530,3529,3941],"class_list":["post-1986","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-accord-studie","tag-advance-studie","tag-diabetes-mellitus-typ-2","tag-haemoglobin-hba1c","tag-hypoglykaemie","tag-ukpds-studie-80","tag-ukpds-studie-81","tag-vadt-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1986"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1986\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}